首页> 外文期刊>The Quarterly Journal of Nuclear Medicine >Gallium scan in adolescents and children with Hodgkin's disease (HD). Treatment response assessment and prognostic value.
【24h】

Gallium scan in adolescents and children with Hodgkin's disease (HD). Treatment response assessment and prognostic value.

机译:在霍奇金病(HD)的青少年和儿童中进行镓扫描。治疗反应评估和预后价值。

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: The aim of the present paper is to describe the accuracy of gallium ((67)Ga) scintigraphy in adolescents and children with Hodgkin's disease (HD). We have studied the diagnostic value of this nuclear imaging technique at disease presentation (staging) and its prognostic value based on changes in (67)Ga uptake observed after treatment (response assessment). METHODS: From April 1985 to July 1999 74 consecutive untreated patients with a median age of 13 y underwent (67)Ga scans 48-72 h after injection of 37-111 MBq of (67)Ga-citrate. Planar whole-body scintigraphy was performed, supplemented with single photon emission tomography (SPET) of the mediastinum from 1996 onwards. Three patients did not undergo further scintigraphic examination because they were treated with radical surgery. After the 1st examination 71 of the 74 patients were monitored by 1-3 (67)Ga scans during the course of their disease. All of them had at least one (67)Ga scintigraphy at the end of the induction phase of chemotherapy, before any other therapeutic regimens were planned. RESULTS: At disease presentation (67)Ga scintigraphy was positive in all patients, detecting 285 of 335 (85.0%) lymph nodal sites of disease. The best sensitivity was observed in the mediastinum (100%; 63/63) and the laterocervical supraclavicular region (85.6%; 125/146); it was lower for axillary (72.7%; 16/22) and retroperitoneal (68.7%; 11/16) lymph node masses. In detecting visceral involvement the sensitivity of (67)Ga scintigraphy was 66.6% (8/12) for lung and 80% (4/5) for bone involvement. Among 71 patients in follow-up, 2 showed rapid progression of disease during induction therapy while 69 patients were monitored for a long period. The response to therapy has been classified according to the changes observed on nuclear medicine or radiological images as complete response (CR) or partial response (PR). On the basis of (67)Ga scans 55 patients (72.4%) were considered as having a CR, while with radiological modalities (chest X-ray, CT, MRI) CR was observed in only 29 patients (40.8%). PR or progression was found with (67)Ga scintigraphy in 16 patients (22.5%) and with radiological modalities in 42 patients (59.1%). (67)Ga scan was concordant with clinical outcome in 97% (28/29). The diagnostic effectiveness of this imaging technique has been analysed by comparing the scintigraphic or radiological changes at the 1st scintigraphic/radiological follow-up examination after induction therapy with the clinical outcome. In this population the relapse rate was 50% (8/16) in the group that did not achieve a CR according to post-treatment (67)Ga scintigraphy, while it was only 10.9% (6/55) in the group that achieved a CR on the basis of scintigraphy findings. The overall survival (OS) and disease-free survival (DFS) were calculated by means of Kaplan-Meier cumulative survival plotting. When the 2 groups of patients with complete (CR) or incomplete normalisation (PR or progression) of (67)Ga scintigraphy were compared, both OS and DFS were found to be statistically different (p=0.0001 and p=0.0004, respectively). By contrast, no statistical difference was found when the radiological findings were considered as the criterion for assessment of tumour response. On the basis of X-ray results the relapse rate was 13.7% in patients with negative post-therapy findings and 23.8% in patients with positive radiological imaging. CONCLUSION: Our data demonstrate the high value of (67)Ga scintigraphy in HD staging in paediatric patients. In addition, evaluation of the (67)Ga uptake is very useful as a prognostic parameter; changes in (67)Ga uptake after therapy indicate a favourable prognosis, whereas children still positive on post-treatment (67)Ga scintigrams should be given more aggressive treatment.
机译:目的:本论文的目的是描述在青少年和霍奇金病(HD)患儿中镓((67)Ga)闪烁显像的准确性。我们已经研究了这种核显像技术在疾病表现(分期)方面的诊断价值及其在治疗后观察到的(67)Ga吸收变化的预后价值(反应评估)。方法:从1985年4月至1999年7月,连续74位中位年龄为13岁的未接受治疗的患者在注射37-111 MBq的柠檬酸(67)Ga后48-72小时接受了(67)Ga扫描。从1996年开始,进行平面全身闪烁显像,并进行纵隔单光子发射断层扫描(SPET)。因为接受了根治性手术,三名患者没有接受进一步的闪烁显像检查。第一次检查后,对74例患者中的71例在其病程中进行了1-3(67)Ga扫描。在计划任何其他治疗方案之前,所有这些患者在化疗诱导阶段结束时至少进行了一次(67)Ga闪烁显像。结果:在疾病表现时(67),Ga闪烁显像在所有患者中均为阳性,在335个淋巴结病灶中检测出285个(85.0%)。纵隔(100%; 63/63)和锁骨上锁骨上区域(85.6%; 125/146)的敏感性最高。对于腋窝淋巴结肿块(72.7%; 16/22)和腹膜后腹膜肿块(68.7%; 11/16)较低。在检测内脏受累方面,(67)Ga闪烁显像对肺的敏感性为66.6%(8/12),对骨受累的敏感性为80%(4/5)。在接受随访的71例患者中,有2例在诱导治疗期间显示疾病进展迅速,而对69例患者进行了长期监测。根据在核医学或放射影像学上观察到的变化,对治疗的反应分为完全反应(CR)或部分反应(PR)。根据(67)Ga扫描,认为55例患者(72.4%)患有CR,而放射学检查(胸部X射线,CT,MRI)仅29例患者(40.8%)出现了CR。 16例(22.5%)的(67)Ga闪烁显像和42例(59.1%)的放射学表现发现PR或进展。 (67)Ga扫描与97%的临床结果一致(28/29)。通过比较诱导治疗后第一次闪烁/放射检查的闪烁或放射学变化与临床结果,分析了该成像技术的诊断效力。在该人群中,根据治疗后(67)Ga闪烁显像术未达到CR的组的复发率为50%(8/16),而达到该组的复发率仅为10.9%(6/55)根据闪烁显像发现的CR。总体生存率(OS)和无病生存期(DFS)通过Kaplan-Meier累积生存图进行计算。比较两组(67)Ga闪烁显像的完全(CR)或不完全正常化(PR或进展)的患者组,发现OS和DFS两者在统计学上是不同的(分别为p = 0.0001和p = 0.0004)。相比之下,当将放射学结果作为评估肿瘤反应的标准时,没有发现统计学差异。根据X射线检查结果,治疗后阴性的患者复发率为13.7%,放射影像学阳性的患者复发率为23.8%。结论:我们的数据表明(67)Ga闪烁显像在儿科患者的HD分期中具有很高的价值。另外,评估(67)Ga的吸收作为预后参数非常有用。治疗后(67)Ga摄取的变化表明预后良好,而治疗后(67)Ga闪烁显像仍阳性的儿童应给予更积极的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号